NOVARTIS PHARMACEUTICALS CORPORATION - PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)

PIID: 36C26226F0048

Signed Date: Jan 20, 2026Effective Date: Jan 2, 2026End Date: Closes in 204 days

Award $

$1.0M

Vendor

NOVARTIS PHARMACEUTICALS CORPORATION

NAICS

325412

Signed Date

Jan 20, 2026

Key Details

Dollars Obligated

$1.0M

Base & All Options

Awarding Agency

Department of Veterans Affairs

Awarding Sub-Agency

Department of Veterans Affairs

NAICS Code

325412 - PHARMACEUTICAL PREPARATION MANUFACTURING

Product Service Code

6505 - DRUGS AND BIOLOGICALS

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

PHOENIX, AZ, 850121136, CD-AZ-01

Description

PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)

Context & Analysis

On Jan 20, 2026, Department of Veterans Affairs obligated $1,023,070.8 to NOVARTIS PHARMACEUTICALS CORPORATION for pluvicto (lutetium lu 177 vipivotide tetra 27mci/ml). The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in PHOENIX, AZ. The contract is scheduled through Jan 1, 2027 — approximately 7 months remaining.